阿尔多斯特的非高血压影响
Natalia Ekman1, Ashley B Grossman2, Anna Nieckarz1
1Department of Hypertension and Diabetology, Medical University of Gdańsk, 80-214 Gdańsk, Poland.
International journal of molecular sciences
|January 25, 2025
概括
阿尔多斯特是血压调节中的关键激素,除了对和平衡的已知影响外,它还影响心血管,免疫和代谢系统. 本综述探讨了这些非高血压效应及其临床相关性.
科学领域:
- 内分泌学 在内分泌学.
- 心血管生理学心血管生理学
- 分子生物学分子生物学
背景情况:
- 阿尔多斯特是一种矿物质皮质激素,通过renin-angiotensin-aldosterone系统 (RAAS) 调节血压和电解质平衡.
- 矿物皮类受体 (MR) 不仅存在于脏中,还存在于心血管,免疫,神经和代谢组织中.
研究的目的:
- 审查阿尔多的非高血压影响.
- 阐明阿尔多的多样化作用背后的细胞机制.
- 要总结与阿尔多的高血压和非高血压影响相关的临床并发症.
主要方法:
- 文献综述,重点关注最近的研究.
- 对阿尔多激素作用的细胞机制的分析.
- 与阿尔多斯特效应相关的临床数据的综合.
主要成果:
- 阿尔多斯特对心血管,免疫和代谢系统产生显著的非高血压影响.
- 阿尔多斯特具有亲氧化和亲纤维性质.
- 在非脏组织中的MR激活介导了这些多样化的效应.
结论:
- 阿尔多的影响超出了血压调节的范围,影响多个器官系统.
- 了解阿尔多的多面性作用对于确定新的治疗点至关重要.
- 对阿尔多的非高血压作用的进一步研究可能会揭示新的临床并发症和治疗策略.
相关概念视频
Antihypertensive Drugs: Potassium-Sparing Diuretics
442
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
442
Antihypertensive Drugs: Direct Renin Inhibitors
480
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
480
Antihypertensive Drugs: Angiotensin II Receptor Blockers
574
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
574
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
462
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
462
Antihypertensive Drugs: Action of β1 Blockers
305
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
305
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375


